Mau-Sørensen, Morten <br/><br/>
A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  May 2015 
 - 1065-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-015-2728-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Bispecific--administration & dosage<br/>Antigens, Neoplasm--biosynthesis<br/>CD3 Complex--biosynthesis<br/>Cell Adhesion Molecules--biosynthesis<br/>Dose-Response Relationship, Drug<br/>Epithelial Cell Adhesion Molecule<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Neoplasms--drug therapy<br/>T-Lymphocytes--immunology